PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Status:
Suspended
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in
people who have been hospitalized with the infection. Participants in the study will be
treated with either PF-07304814 plus current standard of care (SOC), or with placebo plus
current SOC. This is ACTIV-3/TICO Treatment Trial H6.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota
Collaborators:
AIDS Clinical Trials Group Cardiothoracic Surgical Trials Network (CTSN) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Kirby Institute Medical Research Council National Heart, Lung, and Blood Institute (NHLBI) Pfizer Prevention and Early Treatment of Acute Lung Injury (PETAL) University of Copenhagen US Department of Veterans Affairs Washington D.C. Veterans Affairs Medical Center